Lunai Bioworks Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.8M
- Price
- $2.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.05%
- Volume
- 26.5K
About
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Quick stats
Shares outstanding4.5M
Computed float3.1M
Float / shares68.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001527728
AI Summary
AI-generated1/23
standardbullishpartnership
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
Lunai Bioworks signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics to integrate AI-driven patient stratification with human brain organoid models for Parkinson's disease.
The partnership leverages Lunai's BioSymetrics Contingent AI platform and BrainStorm's organoid technology to identify patient subtypes and therapeutic targets, with an initial data readout targeted for the first half of 2027.
The agreement establishes a three-stage commercial strategy focusing on clinical trial design optimization, biomarker panel development, and the creation of partner-ready therapeutic programs.